Major Depressive Disorder

Experts share the results from the first-in-human phase 1 study of this treatment, plus a preview of its upcoming phase 2 trial.

Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.

Here are highlights from the week in Psychiatric Times.

Recent research found approximately 60 documented cases of suicidal ideation and 7 suicide attempts associated with semaglutide use in patients.

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, according to new study.

Here are highlights from the week in Psychiatric Times.

Recent research sheds light on which antidepressants should be preferred as a first option for long-term use.

Here are highlights from the week in Psychiatric Times.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

How can we enhance our lithium research?

Here are highlights from the week in Psychiatric Times.

A more useful measure than BMI or waist circumference? Researchers analyzed the association between weight-adjusted waist index and depressive symptoms.

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The latest in mood disorder news, all in one place.

Here are highlights from the third day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster investigated the relationship between antiobesity agents like semaglutide and depression.

What is new in research on major depressive disorder?

Here are some updates from the world of psychiatry throughout the month of April.

The experts weighed in on a wide variety of psychiatric issues for the April issue of Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

Check out new positive topline data from the SAVITRI study assessing the efficacy and safety of NBI-1065845 in adults with major depressive disorder.